Author Archives: admin


3-D-printed tissues advance stem cell research — ScienceDaily

Tissue engineering and vascular biology expert Guohao Dai, assistant professor in the Department of Biomedical Engineering at Rensselaer Polytechnic Institute, recently won a Faculty Early Career Development Award (CAREER) from the National Science Foundation (NSF).

Dai will use the five-year, $440,000 grant to advance his research into bio-fabricating human tissues with 3-D cell printing technology. Adult neural stem cells are known to hold a great potential for treating disease and damage to the nervous system. However, these cells are both rare and difficult to use in a laboratory setting. The cells lose their potency quickly upon being removed from their native environment, making it difficult to study them.

With his CAREER Award, Dai seeks to design and develop a new way of using 3-D cell printing technology to create a "vascular niche" that replicates the native environment of adult neural stem cells. With the ability to prolong the potency of the cells and precisely control the parameters and components of its vascular niche, researchers would be better positioned to study the cells and their role in treating treat spinal cord injury and neurodegenerative diseases.

"Adult neural stem cells hold so much promise for treating injury and disease, but they are extremely difficult to work with," Dai said. "We believe that we can apply 3-D tissue printing technology to create a vascular niche that will prolong the life of the cells and, in turn, enable new opportunities for studying how they may be used to treat injury and fight disease."

The CAREER Award is given to faculty members at the beginning of their academic careers and is one of NSF's most competitive awards, placing emphasis on high-quality research and novel education initiatives. Dai will collaborate on his CAREER project with two stem cells experts, Rensselaer Associate Professor of Biomedical Engineering Deanna Thompson and Neural Stem Cell Initiative Scientific Director Sally Temple.

Most laboratory cell cultures are 2-D. This is significantly different from the human body, where most cells are in a 3-D environment. A major challenge in creating and studying 3-D tissues is the diffusion limit in the tissues, which quickly lose potency or die without a flow of blood to provide oxygen and nutrients.

To help overcome this challenge, Dai and his collaborators have spent years developing a 3-D tissue printer -- both the hardware and the software. The unique device prints biological tissue by carefully depositing cells, hydrogels, and other materials one layer at a time. Using this platform, Dai developed the technology to create perfused vascular channels, which provide nutrients and oxygen to the printed tissues.

"Blood vessels run throughout almost every part of our bodies, bringing the oxygen and nutrients that allow our cells to survive. The same is true of 3-D cell cultures. They need a vascular system in order to survive," Dai said. "Our device can print 3-D tissues with small channels that function as blood vessels. This enables us to print cells with extracellular matrices that closely replicate those found within the body."

Dai's research team used the 3-D tissue printing technology to help study how the functions of the vascular endothelium -- a thin layer of cells that line entire circulatory system -- are affected by environmental factors such as interactions with blood and smooth muscle cells. A dysfunctional endothelium is known to be a contributor to many vascular diseases including inflammation, thrombosis, and atherosclerosis.

With his CAREER Award, Dai is applying his expertise and unique 3-D tissue printing technology to replicate the native environment of adult neural stem cells. If successful, the project could significantly expand the potency and life span of the cells in laboratory settings, and lead to a better understanding of how this extracellular environment influences the behavior of the cells.

More:
3-D-printed tissues advance stem cell research -- ScienceDaily

ViaCyte asks FDA for go-ahead with human trials of cell replacement therapy for diabetes

ViaCyte, a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, has filed an Investigational New Drug application with the United States Food and Drug Administration, seeking to start a Phase 1/2 clinical trial in patients with type 1 diabetes, it was reported on Friday.

The trial will assess the safety and efficacy of ViaCyte's VC-01 product candidate, a stem cell-derived, encapsulated cell replacement therapy. The company has also submitted a Medical Device Master File to the United States Food and Drug Administration in support of the Encaptra drug delivery system, the device component of the VC-01 product candidate. The company's VC-01 product candidate includes pancreatic progenitor cells, called PEC-01 cells, which are derived from a proprietary human embryonic stem cell line.

Paul Laikind, Ph.D., president and chief executive officer of ViaCyte, said, 'The filing of this IND represents the culmination of many years of research and development by a dedicated team focused on developing a cell replacement therapy for patients with type 1 diabetes and advancing our VC-01 product candidate to human clinical trials. The ViaCyte team has been assisted and supported by the California Institute for Regenerative Medicine (CIRM) a leading organisation focused on advancing the field of stem cell-based technologies, and JDRF, the leading advocacy organisation for patients with type 1 diabetes.'

(C)2014 M2 COMMUNICATIONS http://www.m2.com

Get our daily newsletter or follow us.

Please enter your email below:

Read more from the original source:
ViaCyte asks FDA for go-ahead with human trials of cell replacement therapy for diabetes

Motoneuron-like cell transplantation and GDNF delivery for repair of SCI

PUBLIC RELEASE DATE:

18-Jul-2014

Contact: Meng Zhao eic@nrren.org 86-138-049-98773 Neural Regeneration Research

Adipose-derived stem cells-transdifferentiated motoneurons after transplantation can integrate in the host cord. However, cell survival has been restricted by a lack of ideal environment for nerve cell growth. Taki Tiraihi, Shefa Neuroscience Research Center at Khatam Al-Anbia Hospital, Iran developed rat models of spinal cord injury (SCI) and injected adipose-derived stem cells-transdifferentiated motoneurons into the epicenter, rostral and caudal regions of the impact site and simultaneously transplanted glial cell line-derived neurotrophic factor (GDNF)-gelfoam complex into the myelin sheath. Motoneurons-like cell transplantation combined with GDNF delivery reduced cavity formations and increased cell density in the transplantation site. The combined therapy exhibited superior promoting effects on recovery of motor function to transplantation of GDNF, adipose-derived stem cells or motoneurons alone. These findings suggest that motoneuron-like cell transplantation combined with GDNF delivery holds a great promise for repair of spinal cord injury. Related results were published in Neural Regeneration Research (Vol. 9, No. 10, 2014).

###

Article: "Intraspinal transplantation of motoneuron-like cell combined with delivery of polymer-based glial cell line-derived neurotrophic factor for repair of spinal cord contusion injury" by Alireza Abdanipour, Taki Tiraihi, Taher Taheri (Shefa Neuroscience Research Center at Khatam Al-Anbia Hospital, Tehran, Iran) Abdanipour A, Tiraihi T, Taheri T. Intraspinal transplantation of motoneuron-like cell combined with delivery of polymer-based glial cell line-derived neurotrophic factor for repair of spinal cord contusion injury. Neural Regen Res. 2014;9(10):1003-1013.

Contact: Meng Zhao eic@nrren.org 86-138-049-98773 Neural Regeneration Research http://www.nrronline.org/

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Follow this link:
Motoneuron-like cell transplantation and GDNF delivery for repair of SCI

Montreal woman with leukemia desperately seeks Vietnamese stem cell donors

Leukemia patient Mai Duong is in desperate need of a bone marrow transplant -- something doctors say the Montreal resident requires within a matter of weeks.

While finding a well-matched stem cell donor is already a difficult task, the 34-year-old mother of one faces an added challenge: shes Vietnamese.

Duong was first diagnosed with acute leukemia in 2013, when she was 15 weeks pregnant with her second child. She was forced to terminate the pregnancy as she underwent seven months of chemotherapy, putting her cancer into remission for seven months.

But it returned in May, and doctors gave her two months to find a stem cell match.

"The only option for me to get cured is with the generosity of people," she says.

Duongs case is raising the alarm about a need for stem cell donors among Canada's minority groups, as those in need of transplants are more likely to find a donor from the same ethnic background.

Canadian Blood Services says less than 25 per cent of individuals in need of a stem cell transplant will be able to find a match within their own families and will have to turn to the public inthe hopes of finding a suitable donor.

But ethnic minorities are under-represented on donor lists in North America.

Less than one per cent of registered stem cell donors in Quebec are of South Asian descent, according to Hema-Quebec, the provinces blood services agency. The statistics are similar across Canada and in the international donor database.

"There is a cultural effect and religious effect," spokesperson Susie Joron told CTV News. "The other issue is that the biggest registries are in America and Germany, which has a big Caucasian population."

Read more here:
Montreal woman with leukemia desperately seeks Vietnamese stem cell donors

Montreal woman desperately seeks Vietnamese stem cell donors

Leukemia patient Mai Duong is in desperate need of a bone marrow transplant -- something doctors say the Montreal resident requires within a matter of weeks.

While finding a well-matched stem cell donor is already a difficult task, the 34-year-old mother of one faces an added challenge: shes Vietnamese.

Duong was first diagnosed with acute leukemia in 2013, when she was 15 weeks pregnant with her second child. She was forced to terminate the pregnancy as she underwent seven months of chemotherapy, putting her cancer into remission for seven months.

But it returned in May, and doctors gave her two months to find a stem cell match.

"The only option for me to get cured is with the generosity of people," she says.

Duongs case is raising the alarm about a need for stem cell donors among Canada's minority groups, as those in need of transplants are more likely to find a donor from the same ethnic background.

Canadian Blood Services says less than 25 per cent of individuals in need of a stem cell transplant will be able to find a match within their own families and will have to turn to the public inthe hopes of finding a suitable donor.

But ethnic minorities are under-represented on donor lists in North America.

Less than one per cent of registered stem cell donors in Quebec are of South Asian descent, according to Hema-Quebec, the provinces blood services agency. The statistics are similar across Canada and in the international donor database.

"There is a cultural effect and religious effect," spokesperson Susie Joron told CTV News. "The other issue is that the biggest registries are in America and Germany, which has a big Caucasian population."

Original post:
Montreal woman desperately seeks Vietnamese stem cell donors

Montreal woman pleading with B.C. residents to save her life

VANCOUVER Mai Duong, 34, only has six weeksleft to get a life-saving stem cell or bone marrow transplant and shes pleading with the Lower Mainlands Asian population tosave her.

The mother of one was born and raised in Montreal. Shes had good health for most of her life, until she was diagnosed with leukemia in January 2013, while pregnant with her second child. Doctors told her she had to terminate the pregnancy she was at 15 weeks and start chemotherapy immediately.

Duongwent into remission, but ten months later the cancer was back. And this time it was more aggressive and chemotherapy wouldnt work, she was told. Instead, she needed stem cells or a bone marrow transplant.

Even though Im on the international registry list for donors, I did not have a match for the bone marrow. I was devastated when they told me that, she toldGlobal News.

It turns out the problem of finding a match, and a perfect one at that, is more common among those of Asian descent. In 2012, 2-year-old Jeremy Kong of San Francisco was diagnosed with leukemia and couldnt find a match until he went public. After doing so, he found a nine out of tenbone marrow donor match and underwent a transplant, but died a year later. Experts say Vietnamese, Chinese, Japanese, Korean, Filipino and other South Asian populations are behind Caucasians when it comes to donating blood and organs.

Were severely underrepresented in the international list. So its not even a local or a national problem; its a global problem, said Duong.

Duong is turning to Vancouver because of its large Asian population, and urging people to get tested. She needs a donor of Vietnamese or Filipino descent for a perfect match, and she needs to find them within six weeks or its unlikely shell survive.

For more information on how you can help Duong, visit her Facebook pageor websiteand get tested at OneMatch.ca.

With files from Darlene Heidemann.

Shaw Media, 2014

Read more:
Montreal woman pleading with B.C. residents to save her life

Interleukin-10 aids survival of cells transplanted to repair cardiac tissues after MI

The long-term, positive benefits of transplanted allogenic (other-donated) smooth muscle cells (SMCs) to repair cardiac tissues after myocardial infarction (MI) have been enhanced by the addition of interleukin 10 (IL-10) to the transplanted cells, report researchers in Canada. Their study with rats modeled with MI has shown that SMCs modified with IL-10 - a small, anti-inflammatory protein - benefitted cell survival, improved heart function, and also provided protection against the host's rejection of the allogenic SMCs.

The study will be published in a future issue of Cell Transplantation.

Three groups of rats modeled with MI were treated with SMC injections into the MI-damaged area of the heart. One group received unmodified autologous (self-donated) SMCs; a second group received unmodified allogenic (other-donated) SMCs; the third group received allogenic SMCs modified with IL-10. After three weeks, the unmodified autologous cells had engrafted while the unmodified allogenic cells had been rejected by the hosts. However, the IL-10-modified allogenic cells were found to greatly improve cell survival, improve ventricular function, increase myocardial wall thickness, and also prevent host immune response and rejection of the foreign cells.

"While the most appropriate cell type for cardiac repair remains controversial, mesenchymal stem cells (MSCs) that have been differentiated toward myogenic cells restore ventricular function better, as previous studies have shown," said study co-author Ren-Ke Li of the MaRS Centre in Toronto, Canada. "This study demonstrated that IL-10 gene-enhanced cell therapy prevented immune response, increased survival of SMCs in the heart, and improved cardiac function when compared to the results with the control groups."

The researchers noted that while the use of autologous SMCs donated by patients may be optimal for cell therapy, SMCs self-donated by older, debilitated patients who likely have other serious health problems, have limited regenerative capability. Thus, allogenic SMCs from young, healthy donors are the most beneficial cells, but rejection of foreign cells by the host has been a problem in allogenic cell transplantation. This study suggests that the use of allogenic SMCs modified with IL-10 can prevent host rejection.

"Future studies will be required to determine the long-term effects of IL-10 transduced SMCs to evaluate cell survival and cardiac function at six months and one year," concluded the researchers.

"The use of IL-10 overexpression to reduce rejection of allogenic SMCs is an interesting idea" said Dr. Amit N. Patel, director of cardiovascular regenerative medicine at the University of Utah and section editor for Cell Transplantation. "Further studies will help to determine if this manipulation could prove useful for translation of allogenic SMC therapies to humans".

Story Source:

The above story is based on materials provided by Cell Transplantation Center of Excellence for Aging and Brain Repair. Note: Materials may be edited for content and length.

Visit link:
Interleukin-10 aids survival of cells transplanted to repair cardiac tissues after MI

Weekends with Engadget: Tokyo's vending machines, new buyer's guides and more!

This week, we learned about the dangers of stem cell treatment, explored the world of 3D motion capture and went on a vending machine shopping spree in Tokyo. Read on for Engadget's news highlights from the last seven days. Oh, and be sure to subscribe to our Flipboard magazine!

Stem cells have the potential to be one of modern medicine's most promising advances and we're still learning a lot about how they work. A paralyzed woman in the US discovered this, after an experimental treatment caused her to grow a nose-like tumor on her back.

The virtual simians in Dawn of the Planet of the Apes are impressively lifelike, but 3D motion capture animations haven't always been so awe-inspiring. Read on as Steve Dent explains the history behind this century-old technique.

If you've ever had to break in a new baseball glove, you know that the process take time -- usually a few months at best. Not so with Nike's new fielding mitt.

Why is it so hard to buy a Tesla? It's a combination of archaic laws and a stubborn automotive industry.

Read this article:
Weekends with Engadget: Tokyo's vending machines, new buyer's guides and more!

ViaCyte files investigational new drug application and device master file with FDA for novel cell replacement therapy …

Published 18 July 2014

ViaCyte a privately held regenerative medicine company developing a cell replacement therapy for the treatment of diabetes, announced that it has filed an Investigational New Drug application (IND) with the United States Food and Drug Administration (FDA) seeking to initiate a Phase 1/2 clinical trial in patients with type 1 diabetes.

The trial would evaluate the safety and efficacy of ViaCyte's VC-01 product candidate, a stem cell-derived, encapsulated cell replacement therapy. In a related development, ViaCyte submitted a Medical Device Master File (called MAF) to the FDA in support of the Encaptra drug delivery system, the device component of the VC-01 product candidate.

"The filing of this IND represents the culmination of many years of research and development by a dedicated team focused on developing a cell replacement therapy for patients with type 1 diabetes and advancing our VC-01 product candidate to human clinical trials," said Paul Laikind, Ph.D., President and Chief Executive Officer of ViaCyte. "The ViaCyte team has been assisted and supported by the California Institute for Regenerative Medicine (CIRM) a leading organization focused on advancing the field of stem cell-based technologies, and JDRF, the leading advocacy organization for patients with type 1 diabetes," added Dr. Laikind.

ViaCyte's VC-01 product candidate consists of pancreatic progenitor cells, called PEC-01 cells, which are derived from a proprietary human embryonic stem cell line. These cells are then encapsulated by use of ViaCyte's Encaptra device. When implanted under the skin, the PEC-01 cells are designed to mature and further differentiate into insulin-producing beta and other endocrine cells that regulate blood glucose in a manner similar or identical to the normal islets that comprise the endocrine pancreas.

Based on a pre-IND meeting with the FDA and subsequent consultations, ViaCyte is proposing to initiate clinical evaluation of the VC-01 product candidate directly in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. In addition to evaluating the safety of the product candidate in these patients, the study is designed to demonstrate the effectiveness of the VC-01 product candidate in replacing lost endocrine function that is central to the disease.

In the proposed clinical trial, insulin production from the VC-01 implant would be assessed by measuring C-peptide, a biomarker for insulin produced by beta cells that is expected to provide a sensitive measure of efficacy in these patients. As proposed, the trial would also evaluate secondary end-points related to the need for administration of pharmaceutical insulin to control the disease and the incidence of hypoglycemia, a common side effect associated with pharmaceutical insulin usage.

ViaCyte's proprietary Encaptra device is designed to contain the implanted cells, preventing biodistribution, as well as shielding them from the immune system. Although PEC-01 cells are human cells, they are not the patient's actual cells. As such, they are considered an allogeneic graft, which typically requires immunosuppression in order for the recipient to tolerate the implant. However, the Encaptra device is designed to prevent the patient's immune system from accessing the implanted cells, thereby facilitating successful engraftment and subsequent maturation to islets.

The VC-01 product candidate is designed to be placed under the skin of the patient and can be monitored and readily removed, if or when required. The option to remove the cells is designed to provide an important safety benefit for this novel stem cell-derived cell therapy candidate. It is being regulated as a biologic through interaction with the Office of Cell, Tissue and Gene Therapy within CBER at the FDA. Given the combination product nature of the product candidate, the Center for Devices and Radiological Health at the FDA is also involved in its regulation.

Read the original here:
ViaCyte files investigational new drug application and device master file with FDA for novel cell replacement therapy ...